Gilead Sciences Inc (GILD)

[north40000]

I wonder whether GILD ever investigated this for collaboration/acquisition purposes:

"Peregrine's Bavituximab Shows Promising Anti-Viral Activity and Signs of Prolonged Anti-Viral Effect in Single Dose Monotherapy HCV Trial
TUSTIN, CA, June 7 2006: ……..Joseph Shan, Peregrine's executive director of clinical and regulatory affairs, added, "These first efficacy results in humans are particularly exciting because researchers did not expect to see much anti-viral activity after a single dose of drug, based on our experience in lethal animal disease models such as Lassa fever. Bavituximab demonstrated good anti-viral activity in these studies, but only after administration of multiple doses. Based on the results reported today, the drug's anti-viral potential may be even more promising in humans than the animal models suggest."...."